Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced HER2+Breast Cancer

Interventions

DRUG: Alpelisib
DRUG: Alpelisib matching Placebo
DRUG: Trastuzumab
DRUG: Pertuzumab

Sponsor

Novartis Pharmaceuticals